The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Moderna, a U.S. pharmaceutical company that developed an mRNA-based COVID-19 vaccine, is representative of this trend. It is completing phase 3 clinical trials for its combination vaccine 'mRNA ...